Pancreatic enzyme replacement therapy breaks the usual rules of drug pricing. There is no generic, the five brands cost nearly the same at any given enzyme strength, discount cards barely move the number, and the price you actually pay is set less by the pharmacy than by how many capsules your prescriber tells you to swallow.
That last point is the whole story. Creon and its competitors are dosed with every meal and every snack, so the monthly bill is a capsule count multiplied by a per-capsule price. Two people on the same brand and the same strength can be a thousand dollars a month apart. Every figure below was researched on September 3, 2026, using August 19, 2026 federal acquisition data, 2024 Medicare Part D spending data and cash prices read the same day.
What Does Creon Cost Without Insurance?
The table prices a full month by capsule count. The Low column is 4 capsules a day (120 a month), Average is 6 a day (180 a month) and High is 9 a day (270 a month). Per-capsule prices are the Drugs.com cash prices read September 3, 2026, except the Viokace row, which uses the August 19, 2026 CMS acquisition cost because Viokace is a tablet and its cash price sits outside the sources cited here.
| Product and strength | Low (4/day) | Average (6/day) | High (9/day) |
|---|---|---|---|
| Creon 6,000 lipase units | $267.61 | $401.42 | $602.13 |
| Creon 12,000 lipase units | $525.48 | $788.22 | $1,182.33 |
| Creon 24,000 lipase units | $1,032.25 | $1,548.38 | $2,322.57 |
| Creon 36,000 lipase units | $1,562.42 | $2,343.64 | $3,515.45 |
| Zenpep 10,000 lipase units | $522.31 | $783.47 | $1,175.20 |
| Zenpep 25,000 lipase units | $1,254.53 | $1,881.79 | $2,822.69 |
| Zenpep 40,000 lipase units | $1,995.12 | $2,992.68 | $4,489.02 |
| Pertzye 8,000 lipase units | $337.39 | $506.09 | $759.13 |
| Pertzye 24,000 lipase units | $995.82 | $1,493.73 | $2,240.60 |
| Pancreaze 10,500 lipase units | $420.84 | $631.26 | $946.89 |
| Pancreaze 21,000 lipase units | $832.21 | $1,248.32 | $1,872.48 |
| Viokace 10,440 unit tablet (acquisition cost) | $496.73 | $745.09 | $1,117.63 |
Medicare Part D data is the sanity check on all of this. Across 775,061 Creon prescriptions filled for 185,261 beneficiaries in 2024, CMS recorded an average of $1,926.88 per prescription. Zenpep averaged $2,305.26, Pertzye $3,791.38, Pancreaze $1,565.48 and Viokace $1,310.89. Those are what a real fill costs once actual dosing is baked in, and they land squarely inside the six-to-nine-capsules-a-day band above.
Note the Pertzye result. It has one of the lowest per-capsule prices in the class and the highest average cost per fill. That is not a contradiction, it is the arithmetic of low-strength capsules: fewer enzyme units per capsule means more capsules per meal.
What Drives the Price
Capsule count, ahead of everything else. The FDA label for Creon on DailyMed sets a starting dose of 500 lipase units per kilogram per meal for adults and children 4 and older, with a ceiling of 2,500 units per kilogram per meal and 10,000 units per kilogram per day, plus roughly half the meal dose with each snack. For a 70 kilogram adult that starting point is about 35,000 lipase units at each meal, and the label ceiling is five times higher. That spread, set by your prescriber and by how much fat you eat, is worth thousands of dollars a year.
Capsule strength, which is priced almost linearly. Creon runs $1.93 for the 3,000 unit capsule, $2.23 at 6,000, $4.38 at 12,000, $8.60 at 24,000 and $13.02 at 36,000. Buying enzyme units in bigger packages is marginally cheaper per unit, but not dramatically so, which means switching strengths rarely saves as much as people hope.
The absence of a generic. There is no substitutable generic pancrelipase. Every product in this class is a brand, and the CMS acquisition file confirms it: every Creon, Zenpep, Pertzye and Viokace row is classified as brand. That removes the single biggest cost lever available in almost every other drug category.
Almost no retail margin to discount. Compare acquisition cost with cash price at the same strength on the same day. Creon 24,000 units cost pharmacies $8.34413 in the August 19, 2026 CMS file against a $8.60 cash price. Creon 36,000 was $12.68849 against $13.02. Zenpep 40,000 was $16.19522 against $16.63. Those spreads are 2% to 3%. A discount card cannot squeeze a margin that does not exist.
Bottle size. The only meaningful volume discount we found is on the two strengths Creon sells in a 250-count bottle. At 36,000 units the price falls from $13.02 to $12.24 per capsule, and at 6,000 units from $2.23 to $1.96, so the larger bottle is 6% to 12% cheaper per capsule. On a 270-capsule month at the 36,000 strength that is roughly $210 saved.
Zenpep Cost and the Other Brands
Zenpep is the second most prescribed product in the class, at 259,162 Medicare Part D prescriptions in 2024 against Creon’s 775,061, and it is priced within a few percent of Creon at matching enzyme strengths. Its 10,000 unit capsule is $4.35 cash against Creon’s 12,000 at $4.38. Its 25,000 unit capsule is $10.45. Zenpep also runs to higher strengths than Creon, with 40,000 and 60,000 unit capsules at $16.63 and $24.90, which is why the class ceiling is a Zenpep number: nine 40,000 unit capsules a day is $4,489.02 a month.
Federal acquisition data mirrors that ranking almost exactly. On August 19, 2026 Zenpep cost pharmacies $4.18216 at 10,000 units, $10.14308 at 25,000, $16.19522 at 40,000 and $24.34427 at 60,000.
Pertzye is the low-strength option, with 4,000, 8,000, 16,000 and 24,000 unit capsules at $1.92, $2.81, $5.54 and $8.30 respectively. Pancreaze has the cheapest individual capsule in the class at $0.93 for the 2,600 unit strength, and is the one brand with no rows at all in the CMS acquisition file, so its per-capsule price rests on the Drugs.com cash price alone.
Viokace is the outlier. It is a tablet rather than a delayed-release capsule, and its 10,440 unit tablet cost pharmacies $4.13938 in August 2026. Its 20,880 unit tablet has no fresher acquisition price than a December 31, 2025 vintage of $8.21251, so treat that one as stale.
Cash Price vs. Insurance
This is the rare drug where cash and insurance are not really competing options. At a 2% to 3% retail spread there is no cash discount to find, and the sticker price at every strength is high enough that almost nobody pays it out of pocket for long.
The manufacturer savings cards do not close that gap for uninsured patients, because they are not built for them. AbbVie’s page states the CREON Savings Card is “available to patients with commercial insurance coverage” and excludes anyone in a federal or state program, with a $3,000 annual cap on the standard card and $8,000 on the cystic fibrosis version. The Zenpep, Pertzye and Pancreaze copay cards carry the same commercial-insurance-only structure.
What does exist for cash payers is patient assistance. AbbVie’s own page tells uninsured, unemployed or recently uninsured patients that Creon “may be available, at no additional cost to you, through myAbbVie Assist.” Nestlé Health Science runs a comparable program for Zenpep for uninsured or underinsured patients at or below 150% of the federal poverty level. Pertzye’s assistance program reaches considerably further up the income scale, to 500% of the federal poverty level, and Pancreaze’s reaches 300%. Those thresholds are worth reading carefully, because 500% of poverty is a middle-class income.
How to Pay Less
Apply to the patient assistance program before you pay a single fill. For a drug with no generic and no meaningful retail discount, the manufacturer program is not a fallback, it is the main route. Pertzye at 500% of the federal poverty level and Pancreaze at 300% cover incomes that most assistance programs turn away. These are physician-submitted applications in several cases, so raise it at the visit where the prescription is written.
Ask whether a different strength lowers your capsule count. If you are taking three 12,000 unit capsules per meal, one 36,000 unit capsule costs $13.02 against $13.14 for the three, which is a wash. But if your count drops because a higher strength lets you consolidate snacks, the saving is real. This is a prescriber decision, not a pharmacy one.
Buy the largest bottle your prescription allows. The 250-count Creon bottles are 6% cheaper per capsule than the 100-count at both strengths where a 250-count exists.
Do not waste time on discount cards here. Our comparison of pharmacy acquisition cost against retail cash price found spreads of 2% to 3% across Creon, Zenpep and Pertzye. If you want to understand where cards do and do not help, our comparison of the major discount cards explains which drug categories carry enough margin to be worth carding.
Get the underlying diagnosis worked up somewhere affordable. Enzyme therapy usually follows an endoscopy, imaging or a pancreatic function test, and those bills often dwarf a month of capsules. See endoscopy costs without insurance and colonoscopy costs without insurance before you schedule, and use a federally qualified health center or sliding-scale clinic for the follow-up visits if you are paying cash.
Negotiate the bills around the drug, not the drug itself. Pharmacy prices are close to fixed here, but hospital and specialist bills are not. Our guide to negotiating medical bills and the hospital charity care walkthrough both apply to the GI workup that comes with an exocrine pancreatic insufficiency diagnosis.
The Bottom Line
Creon is a $790 to $2,340 a month drug for most adults at cash prices, and the range is driven by capsule count rather than by which pharmacy you use. The four competing brands land in the same territory, and none of them has a generic to fall back on. If you are paying cash, the highest-value hour you can spend is on a patient assistance application, not on price shopping. For other GI drugs where the cash market behaves more normally, see mesalamine costs, omeprazole costs and Linzess costs.